FDA approves Servier's ALL therapy, acquired in Shire deal

FDA approves Servier's ALL therapy, acquired in Shire deal

Source: 
BioCentury
snippet: 

FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in patients ages one month to 21 years old.